(Total Views: 527)
Posted On: 04/26/2025 7:00:34 PM
Post# of 154693
https://s2.goeshow.com/aai/aai/2025/schedule....06,%202025
IMMUNOLOGY2025™ Program
“Using pregnant rhesus macaques as a model, we evaluated the transplacental transfer of leronlimab, an anti-CCR5 mAb in development for HIV prevention. We further engineered an FcRn-enhanced variant, leronlimab-PLS. Compared to the unmodified mAb, leronlimab-PLS achieved higher maternal concentrations, improved fetal mAb levels, and maintained elevated antibody levels in newborn circulation. A single dose of leronlimab-PLS also ensured complete CCR5 receptor occupancy in mothers and newborns for nearly a month postpartum.”
Diogo Magnani Is speaking.
“MassBiologics is the only nonprofit, FDA-licensed manufacturer of vaccines and biologics in the United States, established in 1894 and transferred to UMass Chan's oversight in 1997 by the Massachusetts legislature. It focuses on developing and producing biologic products (e.g., vaccines, monoclonal antibodies) to address unmet public health needs, including orphan diseases, emerging infections, and global health challenges.“
IMMUNOLOGY2025™ Program
“Using pregnant rhesus macaques as a model, we evaluated the transplacental transfer of leronlimab, an anti-CCR5 mAb in development for HIV prevention. We further engineered an FcRn-enhanced variant, leronlimab-PLS. Compared to the unmodified mAb, leronlimab-PLS achieved higher maternal concentrations, improved fetal mAb levels, and maintained elevated antibody levels in newborn circulation. A single dose of leronlimab-PLS also ensured complete CCR5 receptor occupancy in mothers and newborns for nearly a month postpartum.”
Diogo Magnani Is speaking.
“MassBiologics is the only nonprofit, FDA-licensed manufacturer of vaccines and biologics in the United States, established in 1894 and transferred to UMass Chan's oversight in 1997 by the Massachusetts legislature. It focuses on developing and producing biologic products (e.g., vaccines, monoclonal antibodies) to address unmet public health needs, including orphan diseases, emerging infections, and global health challenges.“
(16)
(0)
